Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus CARDIZEM LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus CARDIZEM LA.
ADALAT CC vs CARDIZEM LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life: 5-8 hours after oral administration. For extended-release formulations, the half-life is similar but the prolonged absorption phase results in sustained plasma concentrations.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Urine (2-4% unchanged, ~40% as metabolites); bile/feces (major route, ~60% as metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker